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Abstract
Background: Leukocytes infiltrating inflamed tissue produce and release opioid peptides such as β-endorphin,
which activate opioid receptors on peripheral terminals of sensory nerves resulting in analgesia. Gene therapy is
an attractive strategy to enhance continuous production of endogenous opioids. However, classical viral and
plasmid vectors for gene delivery are hampered by immunogenicity, recombination, oncogene activation, anti-
bacterial antibody production or changes in physiological gene expression. Non-viral, non-plasmid minimalistic,
immunologically defined gene expression (MIDGE) vectors may overcome these problems as they carry only
elements needed for gene transfer. Here, we investigated the effects of a nuclear localization sequence (NLS)-
coupled MIDGE encoding the β-endorphin precursor proopiomelanocortin (POMC) on complete Freund's
adjuvant-induced inflammatory pain in rats.
Results: POMC-MIDGE-NLS injected into inflamed paws appeared to be taken up by leukocytes resulting in
higher concentrations of β-endorphin in these cells. POMC-MIDGE-NLS treatment reversed enhanced
mechanical sensitivity compared with control MIDGE-NLS. However, both effects were moderate, not always
statistically significant or directly correlated with each other. Also, the anti-hyperalgesic actions could not be
increased by enhancing β-endorphin secretion or by modifying POMC-MIDGE-NLS to code for multiple copies
of β-endorphin.
Conclusion: Although MIDGE vectors circumvent side-effects associated with classical viral and plasmid vectors,
the current POMC-MIDGE-NLS did not result in reliable analgesic effectiveness in our pain model. This was
possibly associated with insufficient and variable efficacy in transfection and/or β-endorphin production. Our data
point at the importance of the reproducibility of gene therapy strategies for the control of chronic pain.
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Background
Exogenous opioids (e.g. morphine), and endogenous opi-
oid peptides, such as β-endorphin (END) and enkepha-
lins, are powerful analgesics in animals and humans [1-3].
Compared to conventional exogenous agonists, endog-
enous opioids have several advantages. These include
reduced probabilities of receptor downregulation and of
paradoxical excitatory effects due to high non-physiologi-
cal exogenous agonist concentrations at the receptor [4].
Gene therapy is an attractive strategy to enhance continu-
ous production of endogenous opioids. The most often
used vectors are recombinant viruses. Several laboratories
have employed herpes simplex virus (HSV) encoding pre-
proenkephalin (PPENK) to increase enkephalin produc-
tion. Transfection of the spinal cord, trigeminal or dorsal
root ganglia (DRG) with such vectors resulted in the atten-
uation of nociceptive behaviors in animal models of acute
and pathological pain [5-13]. Similar effects were found
after hind paw inoculation with HSV encoding endomor-
phin-2 [14] or spinal application of adenoviral and
adeno-associated vectors encoding END in rodents
[15,16].
The immunogenicity of viral vectors, the possibility of
recombination with wild-type viruses, activation of onco-
genes, and their relatively small capacity for therapeutic
DNA have led to the development of non-viral vectors,
mostly plasmids [17]. Gene-gun application or electropo-
ration of plasmids encoding PPENK or END precursor
proopiomelanocortin (POMC) reduced experimental
pain in animals [18-23]. However, plasmids may also
cause undesirable effects such as the production of anti-
bodies (Ab) against bacterial proteins, changes in gene
expression caused by the antibiotic resistance markers and
immune responses to CpG dinucleotide motifs [24-26].
Non-viral, non-plasmid minimalistic immunologically
defined gene expression (MIDGE) vectors may overcome
these problems. MIDGE vectors are linear molecules con-
taining only a promoter, a gene of interest and an RNA-
stabilizing sequence, flanked by two short hairpin oligo-
nucleotide sequences. Important advantages of MIDGE
vectors over plasmids are small size, absence of antibiotic
resistance genes and the relatively low occurrence of CpG
sequences [27,28]. Gene gun delivery into dermis or onto
the eye lid of MIDGE encoding interleukin-12 or cytotoxic
T-lymphocyte-associated antigen-4 and interleukin-4 pro-
tected cats against experimental feline immunodeficiency
virus or improved corneal graft survival in mice, respec-
tively [29,30]. To ensure the effective transport to the
nucleus and transgene expression, a nuclear localization
sequence (NLS) can be attached to the MIDGE. Indeed,
MIDGE-NLS encoding hepatitis B antigen enhanced anti-
viral immunity after intramuscular injection in mice [28].
Also, intradermal administration of MIDGE-NLS encod-
ing LACK antigen (Leishmania homolog of receptors for
activated C kinase) was protective against parasitic infec-
tion in mice [31].
The rationale underlying the present studies was to com-
bine the advantages of MIDGE vectors and the powerful
analgesic properties of opioids creating MIDGE-NLS
encoding POMC to enhance the production of END for
the control of prolonged inflammatory pain. We have pre-
viously shown that END-producing leukocytes accumu-
late in inflamed tissue, where, in response to experimental
stress (swimming in cold water) or to local injection of
releasing agents, the cells secrete this peptide [32-40].
Released opioids bind to opioid receptors on peripheral
sensory nerve terminals, resulting in local analgesia in ani-
mals and in humans [41-46]. Importantly, these events
occur in peripheral tissues and, therefore, lack side effects
such as nausea, respiratory depression, dependence and
addiction mediated by opioid receptors in the central
nervous system [2,3]. Our major objective was to enhance
the production and release of END in inflamed tissue
using POMC-MIDGE-NLS to provide continuous relief of
inflammatory pain.
Methods
Animals and induction of inflammation
Male Wistar rats (200-250 g) (Charité-Universitäts-
medizin Berlin, Campus Benjamin Franklin, Berlin, Ger-
many) received 0.15 ml of complete Freund's adjuvant
(CFA; Calbiochem, La Jolla, CA) into the right hindpaw
under brief isoflurane anesthesia (Abbott, Wiesbaden,
Germany), and were housed individually in cages in
standard experimental conditions [32,34,35]. Experi-
ments were performed according to the guidelines of the
International Association for the Study of Pain [47] and
were approved by the local animal care committee
(Landesamt für Gesundheit und Soziales, Berlin).
Construction and injection of MIDGE-NLS vectors
To prepare POMC-MIDGE-NLS the POMC exon 2-3
cDNA was amplified by RT-PCR. This is because the signal
peptide essential for POMC processing along the regu-
lated secretory pathway is encoded in exon 2 and END is
encoded in exon 3 [40]. The product was cloned into the
pMOK plasmid between the SacI and KpnI restriction sites
and sequenced (Fig. 1A). The pMOK plasmid contains a
kanamycin resistance gene, a cytomegalovirus promoter, a
chimeric intron and a late SV40 pA-site (MOLOGEN AG,
Berlin, Germany). The NLS peptide (PKKKRKVEDPYC;
kindly provided by Dr. P. Henklein, Charité, Berlin, Ger-
many) was coupled to 5'-GGGAGTCCAGTTTTCTGGAC
in a two step procedure using a bivalent crosslinker, as
previously described [28]. The resulting NLS-coupled
ODN was purified by high pressure liquid chromatogra-
phy. The POMC-MIDGE construct was cut out of theMolecular Pain 2009, 5:72 http://www.molecularpain.com/content/5/1/72
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pMOK-POMC plasmid with Eco31I (Fermentas Life Sci-
ence, Vilnius, Lithuania) and the resulting open ended
expression cassette was ligated by T4 DNA ligase (Fermen-
tas) with 5'-phosphorylated hairpin ODNs 5'-AGGGGTC-
CAGTTTTCTGGAC and 5'-GGGAGTCCAGTTTTCTGGAC-
NLS (TIB Molbiol, Berlin, Germany). The mixture was
treated with T7 DNA polymerase (Fermentas) to digest the
remaining plasmid backbone. The resulting POMC-
MIDGE-NLS was purified by anionic exchange column
chromatography (Merck EMD-DMAE, 20 mM TRIS/HCl,
1M NaCl, pH 7).
To obtain a control vector lacking the END sequence (con-
trol MIDGE-NLS) the END sequence within the POMC
coding sequence was replaced by a stop codon. The result-
ing product was amplified, cut with SacI and KpnI (Fer-
mentas) and cloned into the pMOK plasmid between the
SacI and KpnI restriction sites. The resulting plasmid lack-
ing END was used to produce the corresponding control
MIDGE-NLS vector (Fig. 1B), as described above.
To obtain MIDGE-NLS vectors coding for multiple copies
of END the POMC expression cassette was modified by
PCR as follows:
a) The adrenocorticotropic hormone (ACTH) and
melanocyte-stimulating hormone (MSH) fragments were
removed while END sequence was preserved in its origi-
nal place. Therefore, two PCR products were generated:
one consisting of the POMC sequence lacking ACTH and
Construction of MIDGE vectors Figure 1
Construction of MIDGE vectors. (A) POMC exon 2-3 cDNA, encoding the signal peptide, adrenocorticotropic hormone 
(ACTH), melanocyte-stimulating hormone (MSH) and β-endorphin (END), was spliced into the pMOK plasmid between the 
SacI and KpnI restriction sites. The pMOK plasmid contains a kanamycin resistance gene, a cytomegalovirus promoter (PCMV), 
a chimeric intron and simian virus (SV) 40 polyadenylation (pA) site. The POMC-MIDGE-NLS was derived from the pMOK-
POMC plasmid by cutting it with Eco31I, ligation with hairpin ODNs at both ends, and coupling of nuclear localization 
sequence (NLS) to one of the hairpin ODN. The other vectors were prepared analogously by modifying POMC gene as fol-
lows: (B) END sequence was removed to obtain control MIDGE-NLS; (C) ACTH and MSH fragments were removed while 
END sequence was preserved in its original place to obtain 1xEND-MIDGE-NLS encoding 1 copy of END; (D) ACTH frag-
ment was removed, original END sequence was preserved and MSH fragment was replaced with an additional sequence of 
END to obtain 2xEND-MIDGE-NLS encoding 2 copies of END; (E) original END sequence was preserved and the ACTH and 
MSH fragments were replaced with additional END sequences to obtain 3xEND-MIDGE-NLS encoding 3 copies of END.
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MSH and another one, consisting of the END sequence.
The PCR products were cut with Eco31I, ligated and
cloned into the pMOK plasmid after digestion with KpnI
and SacI. The resulting pMOK-POMC-1xEND plasmid
was used to generate the corresponding 1xEND-MIDGE-
NLS vector encoding 1 copy of END (Fig. 1C), as
described above.
b) The ACTH fragment was removed, the original END
sequence was preserved and the MSH fragment was
replaced with an additional sequence of END. Therefore,
a PCR product consisting of the END sequence was ampli-
fied. The product was cut with Eco31I and SacI, ligated
and cloned into the pMOK-POMC1xEND plasmid after
digestion with SacI and BpiI (Fermentas). The resulting
pMOK-POMC-2xEND plasmid was used to generate the
corresponding 2xEND-MIDGE-NLS vector encoding 2
copies of END (Fig. 1D), as described above.
c) The original END sequence was preserved and the
ACTH and MSH fragments were replaced with additional
END sequences. Therefore, two PCR products consisting
of the END sequence were generated. The products were
cut with Eco31I and ligated. The ligated DNA fragment
was cut with BpiI and SacI and cloned into the pMOK-
POMC-1xEND plasmid. The resulting pMOK-POMC-
3xEND plasmid was used to generate the corresponding
3xEND-MIDGE-NLS vector encoding 3 copies of END
(Fig. 1E), as described above.
To examine whether MIDGE-NLS vectors can be taken up
by cells in vivo we also prepared MIDGE-NLS encoding
the bacterial β-galactosidase gene. The gene was amplified
by PCR out of the pCMV-β plasmid (Clontech Laborato-
ries, Mointain View, CA). Recognition sites for KpnI and
XbaI (Fermentas) were generated at the ends of the prod-
uct during the PCR. The product was cut with KpnI and
XbaI and cloned into the pMOK plasmid between the SacI
and KpnI restriction sites. The resulting pMOK-β-galactos-
idase plasmid was used to produce the corresponding β-
galactosidase-MIDGE-NLS vector, as described above.
MIDGE vectors (25-200 μg/100 μl per paw) were injected
into plantar surfaces (intraplantarly; i.pl.) of rat hindpaws
at 4 days after CFA under brief isoflurane anesthesia. Fur-
ther experiments were performed at 2-96 h after vector
injections i.e. 4-8 days after induction of inflammation.
Immunohistochemistry
Twenty four hours after i.pl. injections into both hind-
paws of either β-galactosidase-MIDGE-NLS, POMC-
MIDGE-NLS or control MIDGE-NLS (each at 50 μg) rats
(n = 2) were deeply anesthetized with isoflurane and per-
fused transcardially. The skin with subcutaneous tissue
was dissected from plantar surfaces of both hindpaws and
cut into 7 μm-thick sections, which were mounted on gel-
atin-coated slides, as previously described [48]. Detection
of β-galactosidase was performed by incubating the sec-
tions with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galact-
opyranoside; 1 mg/ml) (Boehringer Mannheim, Vienna,
Austria) as a substrate, for 4 h at 37°C [49].
To detect END the sections were incubated overnight with
rabbit anti-rat polyclonal Ab against END (1:1000; Penin-
sula Laboratories, Merseyside, UK). Staining was per-
formed with a vectastain avidin-biotin peroxidase
complex according to the manufacturer's instructions
using goat anti-rabbit biotinylated secondary Ab and avi-
din-biotin peroxidase (VECTASTAIN Elite Kit, Vector Lab-
oratories, Burlingame, CA, USA), as previously described
[48]. Control experiments for specificity of staining
included overnight preabsorption of the primary Ab with
END and omission of primary or secondary Abs.
Flow cytometry
Twenty four hours after injections of control MIDGE-NLS
(50 μg) or POMC-MIDGE-NLS (25-100 μg) into inflamed
paws, rats (n = 5-6 per group) were killed with an over-
dose of isoflurane and plantar subcutaneous paw tissue
was collected. Single cell suspensions were prepared, as
described previously [35,39], and samples were stained
with phycoerythrin (PE)-Cy5-conjugated mouse anti-rat
CD45 (4 μg/ml; BD Biosciences, Heidelberg, Germany) to
label all hematopoetic cells. To label T cells the samples
were stained with mouse anti-rat CD3-PE (4 μg/ml; BD
Biosciences). For intracellular stains, cells were prepared
as described previously [35,39,48], and incubated with
PE-conjugated mouse anti-rat RP-1 (recognizing granulo-
cytes; 12 μg/ml; BD Biosciences) and fluorescein isothio-
cyanate-conjugated mouse anti-rat CD68 (formerly ED1,
recognizing monocytes/macrophages; 2 μg/ml; Serotec,
Oxford, UK) or 3E7, a monoclonal Ab recognizing the
pan-opioid sequence Tyr-Gly-Gly-Phe at the N-terminus
of opioid peptides (20 μg/ml, subtype IgG2a, Gramsch
Laboratories, Schwabhausen, Germany), as previously
described [39]. A secondary rat anti-mouse IgG2a+b PE Ab
(0.6 μg/ml, BD Biosciences) was employed. Replacement
of the primary Ab with isotype-matched nonimmune
serum was used for negative controls. Absolute numbers
of cells were calculated using Tru-COUNT tubes with
known numbers of fluorescent beads. Data were acquired
using a FACSCalibur and analyzed using the CellQuest
software (all from BD Biosciences).
Radioimmunoassay (RIA)
Twenty four hours after injections of control MIDGE-NLS
(50 μg) or POMC-MIDGE-NLS (25-100 μg) into inflamed
paws, rats were killed and cell suspensions from inflamed
paws were prepared as for flow cytometry (see above).
Cell viability as determined by Trypan blue exclusion wasMolecular Pain 2009, 5:72 http://www.molecularpain.com/content/5/1/72
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> 97%. Cells were pelleted and stored at -20°C. The cell
pellets were lysed in RIA buffer at a concentration of 1 ×
106 cells/100 μl by repetitive freeze-thaw cycles, unsoluble
material was removed by centrifugation, and END immu-
noreactivity was measured in 100 μl of the supernatants
using RIA kits (Peninsula Laboratories and Phoenix,
Blomberg, Germany), as described earlier [38]. Three to
seven cell samples per treatment were obtained and RIA
measurements were performed in duplicates.
Assessment of nociceptive thresholds and antinociception
Rats (n = 6-7 per group) were gently restrained and incre-
mental pressure was applied onto the dorsal surface of the
hindpaws (modified Randall-Selitto method) by means
of an automated gauge (Ugo Basile, Comerio, Italy) by an
experimenter blinded to the treatments. The paw pressure
thresholds (PPT; cut-off at 250 g) required to elicit paw
withdrawal were determined by averaging three consecu-
tive trials separated by 10 s intervals, as previously
described [32,35,48]. In the time-course experiments PPT
were measured at 4 days after CFA before and at 2-96 h
after vector injections. Experiments examining dose-
response relationships of POMC-MIDGE-NLS and effects
of vectors coding for multiple copies of END were per-
formed at 24 h after vector administrations.
To activate endogenous opioidergic pathways of antinoc-
iception in inflamed tissue we used the cold water swim
stress test. Twenty four hours after injection of MIDGE-
NLS vectors the PPT were measured and animals were sub-
jected to swimming for 1 min in a metal container filled
with cold water (2-4°C). Thereafter, rats were dried and
PPT were reevaluated at 1 min and 5 min after swimming,
as previously described [32,35,48].
Statistical analysis
Data are presented as means ± SEM and are expressed in
raw values. Two-sample comparisons were made using
the t-test for independent data and paired t-test for
dependent data. Changes between several groups at one
time point were analyzed by Kruskal-Wallis one-way anal-
ysis of variance (ANOVA) on ranks for not normally dis-
tributed data or by one-way ANOVA followed by the
Bonferroni t-test for normally distributed data. Changes
between two groups over time were evaluated by two-way
ANOVA for repeated measurements followed by the Bon-
ferroni t-test. Differences were considered significant if p
< 0.05.
Results
POMC-MIDGE-NLS transfection efficiency in vivo
To examine whether MIDGE-NLS vectors can be taken up
by cells in vivo rats received MIDGE-NLS encoding the
bacterial β-galactosidase gene into both hindpaws (50 μg;
i.pl.) 4 days after CFA. Histochemistry performed 24 h
after vector injection (i.e. 5 days after CFA) revealed stain-
ing for β-galactosidase. This was visible predominantly in
inflamed paws, while only weak β-galactosidase staining
was seen in noninflamed paws (Fig. 2), similar to other
studies [50], indicating that MIDGE vectors can transfect
cells in vivo. Next, rats received bilateral i.pl. injections of
either POMC-MIDGE-NLS (50 μg) or control MIDGE-
NLS (50 μg). Immunohistochemical staining with END-
specific Ab showed numerous immunoreactive cells in
inflamed, but not in noninflamed, paws (Fig. 2). Morpho-
logically these cells resembled polymorphonuclear and
mononuclear leukocytes, as shown in our previous stud-
ies [38,48]. We did not observe END staining in any other
cell types including neurons. There were no detectable dif-
ferences in END-staining between POMC-MIDGE-NLS
and control MIDGE-NLS (Fig. 2). Control experiments for
specificity of staining did not show END-immunoreactiv-
ity (not shown).
Quantitative analysis with flow cytometry demonstrated
an accumulation of granulocytes, monocytes/macro-
phages and T cells in inflamed paws. Using the 3E7 Ab rec-
ognizing opioid peptides (END, Met-enkephalin and
dynorphin A), we found no significant differences in leu-
kocyte subpopulations and in numbers of opioid-con-
taining immune cells between POMC-MIDGE-NLS and
control MIDGE-NLS (p > 0.05, one-way ANOVA; Table
1).
Effects of POMC-MIDGE-NLS on inflammatory pain and 
on END content in immune cells
Four days after induction of inflammation rats developed
mechanical hyperalgesia manifested by decreased PPT in
inflamed compared with contralateral noninflamed paws,
before control buffer or vector injections (p < 0.001, Fig.
3, Fig. 4A; p < 0.01, Fig. 4B; p < 0.001, Fig. 4C, Fig. 5, Fig.
6) (paired t-test). In Fig. 3B and Fig. 4, for clarity of figures,
only PPT in inflamed paws are shown. We have previously
shown that PPT in contralateral paws are comparable to
PPT before induction of inflammation [51]. There were
no significant differences in PPT of inflamed paws among
groups within each experimental set (p > 0.05, one-way
ANOVA; Fig. 3A, Fig. 4A, B, C, Fig. 5, Fig. 6). To examine
a possible variability in the degree of hyperalgesia
between different sets of experiments (i.e. different fig-
ures), we compared basal PPT in inflamed paws of control
groups (as representative groups) in all figures with each
other. Statistical analysis revealed that PPT in Fig. 4A and
4B were slightly but significantly higher compared with
PPT in Fig. 3A (p < 0.05, one-way ANOVA, Bonferroni t-
test). Equivalent analysis of PPT in noninflamed paws
revealed no significant differences (p > 0.05, one-way
ANOVA; Fig. 3, Fig. 4, Fig. 5, Fig. 6).Molecular Pain 2009, 5:72 http://www.molecularpain.com/content/5/1/72
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Injections of control phosphate buffer (100 μl) into
inflamed paws did not significantly change PPT in
inflamed paws or in contralateral noninflamed paws (p >
0.05, paired t-test; Fig. 3A). At 24 h after injection into
inflamed paws, POMC-MIDGE-NLS (50-100 μg) pro-
duced PPT elevations in inflamed (p < 0.05, one-way
ANOVA, Bonferroni t-test) but not in contralateral nonin-
flamed paws (p > 0.05, one-way ANOVA) (Fig. 3A).
POMC-MIDGE-NLS (50-100 μg) reversed mechanical
hyperalgesia reaching the thresholds of noninflamed
paws (Fig. 3A). Higher doses of POMC-MIDGE-NLS (200
μg) did not further increase the PPT in inflamed (58 ± 3.4
g vs. 56 ± 12 g, 100 μg vs. 200 μg) or in noninflamed paws
(66 ± 1.7 g vs. 64 ± 1.5 g, 100 μg vs. 200 μg) (p > 0.05, t-
Effects of intraplantar POMC-MIDGE-NLS on β-endorphin expression in paws Figure 2
Effects of intraplantar POMC-MIDGE-NLS on β-endorphin expression in paws. β-galactosidase (β-GAL)-MIDGE-
NLS, POMC-MIDGE-NLS or control MIDGE-NLS (each at 50 μg) were injected into both hindpaws at 4 days after induction of 
inflammation. Staining was performed 24 h later. Positive staining for β-GAL (in blue), particularly visible in inflamed paws, indi-
cates that MIDGE vectors can transfect cells (some marked with black arrows) in vivo. β-endorphin (END; brown staining) is 
expressed in immune cells after treatment with POMC-MIDGE-NLS or control MIDGE-NLS. Morphologically these cells 
appear as polymorphonuclear (red arrows) and mononuclear cells (red stars), shown in the dash-boxed inserts at a higher 
magnification of the respective solid line boxes. Bars = 20 μm.
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Table 1: Quantification of leukocyte subpopulations and of opioid-containing leukocytes in inflamed paws following intraplantar 
delivery of POMC-MIDGE-NLS.
Treatment Total cell counts (× 103) per paw
Granulocytes Monocytes/
macrophages
T cells Opioid cells
control MIDGE-NLS 44 ± 13 823 ± 132 62 ± 12 403 ± 65
50 μg
POMC-MIDGE-NLS
25 μg 56 ± 19 566 ± 89 60 ± 14 262 ± 42
50 μg 92 ± 16 633 ± 56 51 ± 6 358 ± 38
100 μg 99 ± 40 691 ± 159 50 ± 11 379 ± 91
Leukocyte counts were determined by flow cytometry. There were no significant differences between control MIDGE-NLS and POMC-MIDGE-
NLS (p > 0.05, one-way ANOVA).Molecular Pain 2009, 5:72 http://www.molecularpain.com/content/5/1/72
Page 7 of 13
(page number not for citation purposes)
test). POMC-MIDGE-NLS (50 μg) injected into inflamed
paws produced significant elevations of PPT for 48 h in
these paws (p < 0.05, two-way repeated measures ANOVA,
Bonferroni t-test; Fig. 3B). There were no significant
changes in the PPT of inflamed paws in the group receiv-
ing control buffer (Fig. 3B) or in the contralateral nonin-
flamed paws (p > 0.05, two-way repeated measures
ANOVA; not shown).
Next, we examined whether there is a correlation between
PPT elevations and END content in immune cells har-
vested from inflamed paws at 24 h following i.pl. MIDGE-
NLS vector injections. We performed three separate sets of
experiments to test reproducibility. In one set, POMC-
MIDGE-NLS elevated PPT of inflamed paws significantly
at 50 μg and 100 μg (p < 0.05, one-way ANOVA, Bonfer-
roni t-test; Fig. 4A), similar to Fig. 3A. POMC-MIDGE-NLS
(25 μg and 50 μg) also enhanced END content in leuko-
cytes, however, a significant effect was observed only after
25 μg (p < 0.05, one-way ANOVA, Bonferroni t-test; Fig.
4A). In another experiment, POMC-MIDGE-NLS (25-100
μg) slightly but non-significantly increased PPT (p > 0.05,
one-way ANOVA; Fig. 4B). Leukocytic END content was
significantly elevated at 25 μg and 50 μg, and decreased at
100 μg (p < 0.05, one-way ANOVA, Bonferroni t-test; Fig.
4B). In the third set of experiments, POMC-MIDGE-NLS
(50-100 μg) significantly elevated PPT (p < 0.05, one-way
ANOVA, Bonferroni t-test; Fig. 4C) but did not produce
significant changes in the END content (p > 0.05, one-way
ANOVA on ranks; Fig. 4C). The control levels of END in
Fig. 4A and Fig. 4B were higher than those in Fig. 4C,
although a significant difference was found only between
Fig. 4A and Fig. 4C (p < 0.05) but not between Fig. 4B and
Fig. 4C (p > 0.05) (one-way ANOVA, Bonferroni t-test).
Together, in all three experiments POMC-MIDGE-NLS
elevated nociceptive thresholds in inflamed paws to a
similar degree, but the effects were moderate and not
always reached statistical significance. POMC-MIDGE-
NLS modestly enhanced END content in immune cells in
some experiments. However these effects were not always
correlated with the effects on nociceptive thresholds.
Swim stress and POMC-MIDGE-NLS effects on 
inflammatory pain
We have previously shown that exposure of rats to a cold
water swim stress leads to the local release of opioid pep-
Effects of intraplantar POMC-MIDGE-NLS on inflammatory pain Figure 3
Effects of intraplantar POMC-MIDGE-NLS on inflammatory pain. (A) Paw pressure thresholds (PPT) were meas-
ured at 4 days after induction of inflammation (white bars), then control buffer (100 μl) or POMC-MIDGE-NLS (25-100 μg/
100μl) were injected into inflamed paws and PPT were re-evaluated 24 h later (black bars). *p < 0.05, compared with control 
buffer at 24 h after its injection (one-way ANOVA, Bonferroni t-test); #p < 0.001, compared with respective PPT of inflamed 
paws before control buffer or vector injections (depicting the development of inflammatory hyperalgesia) (paired t-test). (B) 
Time-course was evaluated at 4 days after induction of inflammation before (0 h) and at 2-96 h after control buffer or vector 
injections (i.e. up to 8 days following induction of inflammation). *p < 0.05, compared with control buffer (two-way repeated 
measures ANOVA, Bonferroni t-test).
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tides from immune cells resulting in antinociception
restricted to the inflamed paws [32,34-36,48]. This stress
paradigm does not significantly change nociceptive
thresholds in animals without inflammation [52]. Here,
we examined whether swim stress can stimulate the secre-
tion of END, possibly overcoming the variability in its leu-
kocytic content, and increase its anti-hyperalgesic actions.
The control vector did not significantly change PPT in
inflamed paws or in contralateral noninflamed paws (p >
0.05, paired t- test; Fig. 5). In this experiment, injection of
POMC-MIDGE-NLS (50 μg) into inflamed paws signifi-
cantly elevated the PPT compared with control MIDGE-
NLS (50 μg) 24 h later in inflamed, but not in contralat-
eral noninflamed, paws (p < 0.05 and p > 0.05, respec-
tively; Fig. 5; compare baselines of control MIDGE-NLS
and POMC-MIDGE-NLS). Subsequently, rats were
exposed to swim stress. In both control MIDGE-NLS- and
POMC-MIDGE-NLS-treated groups there were significant
elevations of PPT at 1 min after swim stress in inflamed
paws (p < 0.05), but there were no significant differences
between the treatments (p > 0.05) (Fig. 5; all comparisons
were analyzed with two-way repeated measures ANOVA
and Bonferroni t-test). There were also no significant
changes in contralateral noninflamed paws (p > 0.05,
two-way repeated measures ANOVA; Fig. 5). Thus, swim
stress produced similar antinociceptive actions after
POMC-MIDGE-NLS as compared with control MIDGE-
NLS.
Effects of POMC-MIDGE-NLS encoding multiple copies of 
END on inflammatory pain
All vectors were injected into both hind paws in a dose of
50 μg, at 4 days after CFA and PPT were measured 24 h
later. Control MIDGE-NLS did not significantly change
PPT in inflamed or in contralateral noninflamed paws (p
> 0.05, paired t-test; Fig. 6). 1xEND-MIDGE-NLS and
Comparison of POMC-MIDGE-NLS effects on nociceptive thresholds and END content in immune cells in inflamed paws Figure 4
Comparison of POMC-MIDGE-NLS effects on nociceptive thresholds and END content in immune cells in 
inflamed paws. The figure shows three separate sets of experiments to test reproducibility (A, B, C). Control MIDGE-NLS 
(50 μg) and POMC-MIDGE-NLS (25-100 μg) were injected into inflamed paws at 4 days after induction of inflammation. Effects 
of vectors on paw pressure thresholds (PPT; upper panels) and on END content in immune cells (lower panels) were meas-
ured in parallel 24 h after their injections (black bars). PPT were also measured before vector injections (white bars). *p < 0.05, 
compared with control MIDGE-NLS at 24 h after its injection (one-way ANOVA, Bonferroni t-test).
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2xEND-MIDGE-NLS significantly, but slightly, elevated
PPT compared with the control vector (p < 0.05; t-test; Fig.
6). POMC-MIDGE-NLS and 3xEND-MIDGE-NLS did not
significantly change PPT compared with the control vector
(p > 0.05, t-test; Fig. 6). The PPT in contralateral nonin-
flamed paws were not significantly changed by any of the
treatments (p > 0.05, t-test; Fig. 6).
Discussion
In the present study we examined the control of pro-
longed inflammatory pain with novel END-coding
MIDGE vectors, which lack the disadvantages of classical
viral and plasmid vectors. Although, POMC-MIDGE-NLS
injected into inflamed tissue appeared to be taken up by
leukocytes in vivo (Fig. 2, Fig. 4), its anti-hyperalgesic
actions were rather moderate and not consistently repro-
ducible (Fig. 3, Fig. 4, Fig. 5, Fig. 6). Also, these effects
could not be enhanced by increasing END release through
stress or by modifying POMC-MIDGE-NLS to code for
multiple copies of END (Fig. 5, Fig. 6).
Previously we have consistently observed significant anal-
gesic effects of both exogenous and leukocyte-derived opi-
oids against mechanical stimulation in experimental and
clinical inflammatory pain [2,3]. In the current study, i.pl.
injection of POMC-MIDGE-NLS reversed mechanical
hyperalgesia, i.e. nociceptive thresholds returned to the
levels measured in contralateral noninflamed paws in
some experiments (Fig. 3, Fig. 4A, Fig. 5). Nevertheless,
the effects were rather moderate and not always reproduc-
ible (Fig. 4B, C, Fig. 6). This lack of consistently significant
anti-hyperalgesic effects of POMC-MIDGE-NLS might be
related to higher basal PPT (after CFA but before vector
injections) and bigger within-group variability of
responses in some experiments (Fig. 4B, Fig. 6). In some
previous reports hyperalgesia was fully reversed by opioid
peptide vector delivery. For example, intrathecal electro-
poration of modified POMC plasmids suppressed ther-
mal hyperalgesia in a neuropathic pain model [23], and
PPENK-HSV applied to the paw skin reversed thermal
hyperalgesia induced by pertussis toxin or capsaicin
[5,11,12]. However, similar to our results, the majority of
studies using either HSV, adenovirus, adeno-associated or
plasmid vectors encoding opioid peptides found only par-
tial and modest reductions of thermal or mechanical
hyperalgesia in long-lasting (weeks) or short-lasting (1-3
h) pain models [8-10,13,15,16,18-23]. A reproducibility
of anti-hyperalgesic effects has not been reported in those
earlier studies.
POMC-MIDGE-NLS decreased hyperalgesia for about 2
days. This is much shorter than the effects measured for 2-
20 weeks after injections of viral vectors encoding opioid
peptides [5,7-14,16], or up to 2 weeks after endomorphin-
2-HSV or POMC plasmid applications [14,20,23]. How-
ever, in other studies using END-coding adenoviral vector
Swim stress and POMC-MIDGE-NLS effects on inflammatory pain Figure 5
Swim stress and POMC-MIDGE-NLS effects on inflammatory pain. Paw pressure thresholds (PPT) were measured at 
4 days after induction of inflammation (white bars), then control MIDGE-NLS (50 μg; gray bars) or POMC-MIDGE-NLS (50 μg; 
black bars) were injected into inflamed paws and PPT were re-evaluated 24 h later (baseline, BL). Next, rats were exposed to 
cold water swim stress and PPT were re-examined 1 min and 5 min later. *p < 0.05, compared with the BL of control MIDGE-
NLS; +p < 0.05, compared with respective BL (two-way repeated measures ANOVA and Bonferroni t-test); #p < 0.001, com-
pared with respective PPT of inflamed paws before vector injections (depicting the development of inflammatory hyperalgesia) 
(paired t-test).
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or POMC plasmids, attenuation of hyperalgesia was only
measured in short-lasting (30 min-3 h) pain models
[15,18,19,21,22]. Thus, longer-lasting anti-hyperalgesic
effects were mostly produced by viral vectors preferen-
tially targeting neurons [5,7-14,16]. In contrast, in our
model MIDGE-NLS appeared to be taken up mostly by
immune cells. At this stage of inflammation (5 days fol-
lowing CFA) monocytes/macrophages dominate, and
their turnover rate of several hours correlates with the
time-course of POMC-MIDGE-NLS-mediated anti-hyper-
algesia. On the other hand, the 48 h-lasting elevation of
nociceptive thresholds produced by POMC-MIDGE-NLS
is superior to the 5-10 min-lasting effects after i.pl. END
injection [48]. Hence, some of our experiments demon-
strated a clear prolongation of anti-hyperalgesic actions
by POMC-MIDGE-NLS-based END delivery. Modification
of POMC-MIDGE-NLS vectors to also transfect neurons
might be an interesting future approach for improvement
of their anti-hyperalgesic effects.
In some of our experiments POMC-MIDGE-NLS slightly
elevated END content in immune cells accumulating in
inflamed tissue. However, these effects were not always
statistically significant or directly correlated with the
attenuation of hyperalgesia, indicating variability in trans-
fection and/or END production efficacy. Although there
was some variability in the control END levels among
experimental sets (Fig. 4) this does not seem to predict the
efficacy of POMC-MIDGE-NLS in END production. For
example, even though the control END levels in Fig. 4A
and Fig. 4B were comparable, the END levels after differ-
ent doses of POMC-MIDGE-NLS varied between the two
graphs. Also, it seems that there was no direct correlation
between the control END levels and the extent of hyperal-
gesia. Thus, despite differences in the control END levels
in Fig. 4A, B and 4C, the basal PPT (after CFA but before
control vector injection) were comparable among these
three graphs. The lack of significant increases in the num-
bers of opioid-positive leukocytes suggests that when
POMC-MIDGE-NLS transfected these cells it was mostly
active in those already expressing the peptide. Other vec-
tors have been shown to increase opioid peptide produc-
tion in different tissues. For example, HSV-PPENK applied
to skin enhanced the expression of PPENK, Met- or Leu-
enkephalin in the spinal cord and primary afferent neu-
rons in healthy animals [5,7,11-13]. Spinal application of
adenoviral vectors encoding END resulted in increased
cerebrospinal fluid levels of the peptide [15]. Importantly,
while antinociceptive effects were assessed after induction
of inflammation or neuropathy, the transfection efficacy
Effects of intraplantar POMC-MIDGE-NLS encoding multiple copies of β-endorphin (END) on inflammatory pain Figure 6
Effects of intraplantar POMC-MIDGE-NLS encoding multiple copies of β-endorphin (END) on inflammatory 
pain. Paw pressure thresholds (PPT) were measured at 4 days after induction of inflammation (white bars), control MIDGE-
NLS, POMC-MIDGE-NLS and vectors with 1-3 copies of END (1-3xEND-MIDGE-NLS) (each at 50 μg) were injected into 
both hind paws and PPT were re-evaluated 24 h later (black bars). *p < 0.05, compared with control MIDGE-NLS at 24 h after 
its injection (t-test); #p < 0.001, compared with respective PPT of inflamed paws before vector injections (depicting the devel-
opment of inflammatory hyperalgesia) (paired t-test).
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of these viral vectors in peripheral neurons was primarily
verified in healthy animals [5,7,11-13,16]. There was no
clear explanation for these approaches and they make
interpretation of the data difficult. Transfection efficacy of
plasmid vectors was evaluated either directly in inflamed
tissues treated with the vectors, or in the spinal cord after
intrathecal electroporation. For instance, gene-gun appli-
cation of plasmids coding for POMC or PPENK to
inflamed rat paws or into the bladder wall, or intrathecal
electroporation in animals with hind paw inflammation
or with sciatic nerve injury increased levels of END or Met-
enkephalin in the respective tissues, although cell types
were not specified in those experiments [18-23]. None of
those previous studies reported transfection of immune
cells with vectors encoding opioid peptide precursors.
MIDGE vectors do not seem to possess particular charac-
teristics in cell type targeting. In previous studies their
transfection efficacy was examined predominantly in vitro
in various cell lines. Accordingly, MIDGE-NLS encoding
hepatitis B antigen transfected chicken hepatoma cells
[28], MIDGE-NLS encoding LACK antigen was successful
in transfecting kidney COS-7 cells [31], and MIDGE
encoding IL-12 transfected a feline T lymphocyte line
[29]. Hence, it appears that if a vector is introduced into a
cell line or tissue, cells are "forced" to express a transgene
regardless of the physiological/pathological state of the
tissue. This might explain some (scarce) staining in non-
inflamed paws after β-galactosidase-MIDGE-NLS applica-
tion in our current study. On the other hand, it is reason-
able to assume that the type of transfected cells might be
determined by the pathological condition of the tissue.
Thus, in our studies it appears that when tissue is inflamed
and infiltrated by leukocytes, these cells might be a major
target for POMC-MIDGE-NLS.
Our studies do not provide direct evidence for the opioid-
receptor selectivity and the site of anti-hyperalgesic
actions of END coded by POMC-MIDGE-NLS. Testing
specific and peripherally-restricted opioid receptor antag-
onists would be necessary to determine selectivity and site
of the vector actions. However, because of the variable
reproducibility of POMC-MIDGE-NLS-mediated anti-
hyperalgesic effects, such experiments are difficult to per-
form. Similar concerns apply to the effects of POMC-
MIDGE-NLS encoding 1 or 2 copies of END, as they pro-
duced only minor PPT elevations. Nevertheless, an action
via peripheral opioid receptors is most likely. The fact that
Abs recognizing endogenous END were reactive in our
immunohistochemical and RIA experiments suggests that
POMC-MIDGE-NLS-induced END is not different from
authentic END and therefore should act at opioid recep-
tors. We have previously shown that opioid peptides
injected directly into inflamed tissue can produce antino-
ciception via opioid receptors on peripheral sensory neu-
rons [2,3,48]. Furthermore, direct application to injured
tissues of either HSV-PPENK or POMC plasmid resulted
in peripheral opioid receptor-selective anti-hyperalgesic
effects [6,7,13,21]. In contrast, applications of POMC-
MIDGE-NLS (Fig. 6), POMC plasmid or of exogenous opi-
oids into peripheral non-injured tissues [2,3,21,48] did
not significantly change nociceptive thresholds. Most
probably this is related to an intact perineural barrier and/
or insufficient number or G-protein coupling of opioid
receptors on sensory neurons in noninflamed tissues
[2,3,43,44,46].
Conclusion
In this study we have evaluated the effectiveness of a novel
non-viral, non-plasmid MIDGE-NLS vector coding for
END in the control of prolonged inflammatory pain. We
show evidence of an enhanced antinociceptive response,
uptake by immune cells and increased content of END.
However, these effects were not always reproducible or
directly correlated with each other. Thus, while MIDGE
based vectors were effective against infections and in
improving graft survival [28-31] anti-hyperalgesic effects
of POMC-MIDGE-NLS were not reliably reproducible in
our studies. Enhancing opioid secretion from leukocytes
by stress [32,34,35,48] did not improve these effects,
although this might have been masked by a relatively
strong swim-stress induced antinociception. Further, the
modification of POMC-MIDGE-NLS vectors to code for
multiple copies of END did not produce better effects
either. Thus, variability in transfection and/or END pro-
duction efficiency of POMC-MIDGE-NLS appears to limit
their potential antinociceptive actions in our model of
painful paw inflammation. Noteworthy, our studies show
that pain modulation by gene therapy might be suscepti-
ble for vector transfection variability, which should be
addressed in future studies.
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